Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, L. Morales et al.|Annals of Oncology|2021Cited by 724
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Min Yan et al.|BMJ|2023Cited by 82
miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2Fei Liu, Cuizhi Geng|International Journal of Oncology|2018Cited by 41
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Tao Sun et al.|Journal of Clinical Oncology|2022Cited by 36
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.Min Yan, Yajing Feng, Huimin Lv et al.|Journal of Clinical Oncology|2024Cited by 7